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Chondroblastoma of bone in extremities. - A single centre study of 177 cases. 
 
Introduction 
Chondroblastoma is a rare benign bone tumour that typically arising in children and young adults. 
These cartilaginous tumours are classically found in the epiphysis or apophysis of long bones, most 
commonly the proximal tibia followed by proximal femur and proximal humerus.[1]  
Chondroblastomas are usually symptomatic and rarely discovered incidentally on plain radiographs. 
The tumour is classified as benign, although some extremely rare cases of pulmonary metastases 
have been reported.[2] While straightforward cases with classical features may lead to a quick 
diagnosis, there are few other tumours like giant cell tumour (GCT) and aneurysmal bone cyst 
(ABC) that might give an overlap in clinical presentation, radiological feature, and the presence of 
giant cells and hemosiderin on microscopic examination. However, recent studies by Behjati et al 
and Presneau et al have identified a K36M mutation in either H3F3A or H3F3B gene. This gene 
mutation 70%-95% specific for chondroblastoma. In GCT a separate specific mutation of G34M in 
H3F3A gene has been found. Surgery has remained the mainstay of treatment, usually meticulous 
curettage of the lesion followed by filling the osseous defect with bone auto/allograft, bone 
substitute or cement. Recently radiofrequency ablation has also been introduced in the treatment of 
chondroblastoma.[3, 4] 
Local recurrence after treatment varies considerably, ranging from 10% to 35%; predisposing 
factors for local recurrence are not clear, but location, young age and epiphyseal location at the time 
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of diagnosis may increase the risk[5-7] though this is not clear from the available evidence 
Sailhan[1]. 
The aim of this study was to perform a retrospective analysis of all patients undergoing treatment 
for chondroblastomas. The objectives of this study were to describe the clinical and radiological 
characteristics of chondroblastoma, and to analyse the recurrence rate and complications associated 
with surgery giving specific attention to lesions arising in the proximal femur. 
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Material and methods 
This retrospective study included 177 patients, identified from a prospectively maintained database, 
who had been diagnosed with a chondroblastoma of the extremity between 1990 and 2015 at a 
single tertiary referral centre. All patients were diagnosed and treated at this single centre.  Those 
who were primarily treated elsewhere and referred for the management of a recurrence were 
excluded. The multidisciplinary team (MDT) diagnosis was based on clinical, radiological and 
histological criteria. Details of the clinical data collected, at the time of presentation and local 
recurrence, included the site (appendicular, extremity or pelvis), primary tumour size (cm), type of 
operation at the time of primary or local recurrence, presenting symptoms and their duration, 
gender, age, pathological features and functional and oncological outcomes including local 
recurrence free survival (LRFS).  Resection and LR specimens were examined by specialised bone 
sarcoma pathologists. The histopathology was studied with special emphasis as to whether there 
was evidence of an associated aneurysmal bone cyst.  
The radiographs at presentation were reviewed for the site and size of the lesion. The status of the 
adjacent physis was also determined and recorded as either open or closed.  
Statistical analysis 
Descriptive statistics were used to display demographic data. The Kaplan-Meier method was used 
to determine LRFS. Survival rates were calculated from the date of operation to the date of LR. 
Kruskal-Wallis test was used for statistical analysis means between the groups. Univariable analysis 
was performed by comparing groups with log-rank test with subsequent multivariable Cox 
proportional hazard analysis of significant variables to identify predictors of LRFS. A p value <0.05 
was considered significant. All statistical analysis was completed using SPSS Statistics 24.0 (IBM, 
New York, USA.  
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Results 
The most commonly affected site was the proximal tibia (20.2%)(Figure 1a and b), followed by 
proximal humerus (19.1%), proximal femur (18.0%)(Figure 2 a and b), distal femur (15.7%) and 
foot (14.6%). In the foot, 7/26 (27%) originated in calcaneus, 18/26 (69%) in talus and one (4%) in 
the navicular. In the proximal femur, 18/32 (56%) were located in the greater trochanter and 14/32 
(44%) in the femoral head. The location of tumours is summarized in figure 3.  
Two patients presented with a pathological fracture, one in the proximal femur and one in the 
olecranon. Delays in diagnosis were common. The median duration of symptoms was 36 weeks, but 
the range was wide, ranging from no symptoms prior to pathologic fracture to 10 years of pain. 
Two patients developed metastatic disease, which was confirmed by histological analysis of the 
metastases to be chondroblastoma. After metastasectomy one patient has subsequently died of the 
disease and one patient is alive having undergone lung metastastectomy following bone specific 
chemotherapy. In both cases the histology was later carefully re-reviewed without changed in the 
diagnose.  
Local recurrence (LR) was seen in 25/177 (14%) patients. The mean time to LR was 18 months 
(range 3-158 months) following initial treatment. The median time to LR was, however, 10 months 
as in all but one case, LR occurred within 24 months. In this one outlying case, a 24 year-old male, 
who presented with a chondroblastoma in the proximal tibia initially treated by curettage, 
developed minor symptoms 10 years after initial treatment. Imaging and histology confirmed 
recurrent chondroblastoma which was treated with repeat curettage and augmentation with cement 
13 years after the primary operation. Of the 25 cases of LR, 7 patients had two LRs and 18 had only 
1 episode of LR. LR was most common for tumours of the proximal tibia (22.2%).  
In 26% of cases, a secondary aneurysmal bone cyst (ABC) component was seen on histology. This 
feature was most common for chondroblastoma of the foot, where 46% of the cases were reported 
to have a significant ABC component. (Figure 4 a and b) The results are summarized in table I. 
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Surgical treatment 
116/177 (65%) cases were treated by curettage alone, without augmentation or packing of the 
defect. In 33 cases (18.6%), the post curettage defect was packed with autologous bone graft whilst 
only 3 cases (1.7%) were augmented by cement. Radiofrequency ablation (RFA) was used in 22 
(12.4%). The decision to use RFA was determined on a case by case basis following discussion at a 
multidisciplinary team meeting. In general, RFA was considered for smaller lesions (<2cm) away 
from critical structures (including subchondral lesions when RFA risked damage to the overlying 
cartilage), without a soft tissue component.  Endoprosthetic replacement was required in two cases 
and osteoarticular allograft was used in one patient. Local recurrence developed in 17/116 (14.7%) 
cases after curettage, 3/22 (13.6%) after RFA, 4/33 (12.1%) after curettage with bone grafting and 
none after endoprosthetic replacement, curettage with cementation or osteoarticular allograft. 
Local recurrence free survival 
Local recurrence free survival (LRFS) at 1-year was 90.3% and 84.7% at 2-years. Age was a 
significant risk factor for local recurrence (HR 0.856, 95% CI 0.768-0.955, p=0.005). 
Proximal femur 
32/177 (18%) lesions arose in the proximal femur. 18/32 (56%) were located in the greater 
trochanter and 14/32 (44%) in the femoral head. The mean age was statistically lower in tumours 
located in femoral head when compared to the greater trochanter (19.5 years compared to 13.9 years 
(p=0.004)), as was the mean size of tumour (53 mm for greater trochanter tumours compared to 26 
mm in femoral head lesions (p=0.001)). Among femoral head tumours, the physis was open in 7/14 
patients (50%). (Figure 5) Tumours located in the greater trochanter were all curetted without 
further complications or LR. Tumours located in the femoral head were treated in a number of 
different ways, largely dependent on the location of the lesion. Curettage via a lateral, 
subtrochanteric entry drill hole, was used in 6/14 cases. An open approach to the femoral neck, 
raising a trapdoor in the femoral neck was used in 2/14 cases. In 2 cases, an open approach to the 
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femoral head was used to allow a chondral flap to be elevated and curettage of the underlying 
lesion. The remaining 5 cases underwent RFA.  
Local recurrence was seen more frequently in femoral head tumours when compared to tumours 
located in the greater trochanter, though the numbers were too small to give statistical significance; 
3/14 (21%) and none, respectively (p=0.073).  All LRs in femoral head tumours occurred in patients 
treated by a minimally invasive approach via a drill along the femoral neck. One patient eventually 
developed femoral head collapse and one had a growth plate fusion ending in slight limb length 
discrepancy without further treatment. Results of proximal femur tumours are summarised in table 
II.   
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Discussion 
Chondroblastoma is a rare benign to intermediate grade bone tumour. There are few larger studies 
published in the literature[1, 5, 7-10], but to our knowledge this is the largest single centre study 
looking at the radiological, surgical and clinical aspects of the disease, and recurrence following 
treatment.   
 
There was a strong male preference, with a male:female ratio of 2.3 to 1. Our results are in 
accordance with the literature, where male:female ratio has been varying between 1.56 and 3.48 to 
1.[1, 9, 10]
 
 The mean age of 18 years is in accordance with other publications and thereby our 
study resembles a very typical cohort of patients with chondroblastoma.  
 
A cystic (aneurysmal bone cyst, ABC) component is seen often in chondroblastomas. The role of 
the ABC component is interesting and has been discussed in previous publications. Some authors 
have suggested that the cystic component is seen more often in cases with local recurrences[7, 11, 
12] however, other series have not confirmed this[1, 7, 13]. In our results, we did not see any 
correlation between ABC rich chondroblastomas and the incidence of local recurrence. The overall 
rate of ABC rich chondroblastoma was 26% in our study, which is in accordance with the previous 
literature where the overall rate of ABC rich chondroblastomas has varied between 23%-25%.[5, 
14] If secondary ABC formation included microcystic degeneration with haemorrhage, the rate of 
ABC formation has been reported to increase as high as 83%.[10] The definition of ABC rich 
chondroblastoma is vague, and in this study a significant amount, more than 50% of the surface, 
was required to present with ABC component, before the tumour was labelled as an ABC rich 
chondroblastoma. In our study, we observed that a significant ABC rich component was most often 
located in chondroblastomas in small bones like the patella and the bones of the foot. This may be 
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of clinical significance where a solitary ABC is diagnosed and further nonsurgical sclerotherapy is 
considered as a treatment option. 
The proximal femur was the third most common location after the proximal tibia and proximal 
humerus which is in accordance with the current literature.[1, 5] Tumours in the proximal femur are 
located more often in the greater trochanter than in the femoral head. Several differences were 
noted when femoral head tumours were compared to those of the greater trochanter. Tumours in the 
greater trochanter were significantly larger and occurred in older patients, when compared to those 
of the femoral head. The mean age was 19.5 years in comparison to 13.9 years in patients with 
femoral head tumours. In patients with femoral head tumours, the growth plate was open in half of 
the patients.  
 
Surgical treatment of greater trochanteric lesions was associated with no local recurrences. This 
may well be due to the ease of access to this location allowing a more detailed curettage. Treatment 
of femoral head tumours can be extremely challenging, particularly in children with open physes, or 
for tumours abutting the subchondral plate where curettage or RFA risks the overlying cartilage. In 
the past, the traditional approach to the femoral head has been via subtrochanteric drill hole in the 
lateral femur. Gaining surgical access through the femoral neck to the femoral head results in a 
higher incidence of LR, presumably due to the poor access afforded to allow a detailed curettage of 
the lesion. In our experience, the rate of local recurrence was three out of six treated by a 
transcervical approach, and none in those treated by a direct approach. A direct hip join approach 
provided good access and exposure of the lesion. Interestingly, secondary femoral head collapse, 
either due to an unstable cartilage defect or due to avascular necrosis, was not seen in any of the 
patients treated by this approach.   
Previous series, and our results show, RFA to be an attractive option for treatment of 
chondroblastoma.[3, 4, 15-18] In the femoral head, we observed no local recurrences after RFA, 
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and when including all anatomical locations treated with RFA, the rate of local recurrence was 
comparable to curettage. There was a learning curve to RFA as demonstrated by the higher 
incidence of LR seen in cases treated by RFA in the early phase of the study population. However, 
it should be noted that when first adopted as a treatment option, it was largely reserved for 
challenging tumour locations such as the posterior aspect of the proximal tibia and femoral head, 
making direct comparison with more traditional surgical treatments difficult. Having demonstrated 
its efficacy, of course, RFA is now employed for far more lesions dependant largely on the size and 
location of the tumour. We did, however, observe more LR following RFA in the early part of the 
study mostly likely representative of the learning curve of the procedure. In addition, at the early 
stages, RFA was selected as the treatment option for cases of chondroblastoma in challenging 
locations, including the posterior tibia plateau and femoral head. However, following initial 
successes with the approach, this has now been expanded to all locations that fulfil the criteria for 
its use.  
The overall rate of local recurrence was 13.6%, which is in accordance with the literature. The only 
factor identified as a significant risk for LR was young age, known to be a risk factor for local 
recurrence.[7] Whilst the posterior part of proximal tibia had the highest rates of local recurrence, 
there was no significant difference in comparison to other locations in terms in relation to LR.  
 
Chondroblastoma is often regarded as a benign condition, despite the recent reclassification of the 
tumour as an intermediate grade lesion with local aggressiveness and a small risk of metastasis.[19] 
The incidence of metastases is rare with only a few individual reports in literature[20, 21]. A few 
larger series have reported the incidence to be between 2.7% and 3.3%[5, 8] though this was not the 
finding in this study. In some other large published studies, the rate of metastasis was not been 
reported or did not exist,[1, 5, 7, 9, 10] raising questions about the histological classification of the 
primary tumour in those series that report a higher incidence. The incidence of metastasis of 1.1% 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
in our study is, we believe, is more reliable, as our series presents the largest available in the 
literature, and all cases of both primary lesions and metastatic lesions, were reviewed by experience 
musculoskeletal pathologists. 
 
Conclusions 
In conclusion, although usually categorized as benign, chondroblastoma has metastatic potential. 
Whilst rare, occurring in only 4.5% of cases, the femoral head location for chondroblastoma raises 
distinct challenges for treatment as they often occur in young patients with open growth plates. 
Where tumours of the femoral head occur, the preferred treatment should be by RFA where lesions 
are amenable, or by formal open procedures due to the high incidence of LR seen with less invasive 
approaches.   
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
References 
[1] F. Sailhan, F. Chotel, R. Parot, Sofop, Chondroblastoma of bone in a pediatric population, J 
Bone Joint Surg Am 91(9) (2009) 2159-68. 
[2] L.B. Kahn, F.M. Wood, L.V. Ackerman, Malignant chondroblastoma. Report of two cases and 
reviw of the literature, Arch Pathol 88(4) (1969) 371-6. 
[3] C. Xie, L. Jeys, S.L. James, Radiofrequency ablation of chondroblastoma: long-term clinical 
and imaging outcomes, European radiology 25(4) (2015) 1127-34. 
[4] R.K. Lalam, G.L. Cribb, B.J. Tins, W.P. Cool, J. Singh, P.N. Tyrrell, V.N. Cassar-Pullicino, 
Image guided radiofrequency thermo-ablation therapy of chondroblastomas: should it replace 
surgery?, Skeletal radiology 43(4) (2014) 513-22. 
[5] A.J. Ramappa, F.Y. Lee, P. Tang, J.R. Carlson, M.C. Gebhardt, H.J. Mankin, Chondroblastoma 
of bone, J Bone Joint Surg Am 82-A(8) (2000) 1140-5. 
[6] D.S. Springfield, R. Capanna, F. Gherlinzoni, P. Picci, M. Campanacci, Chondroblastoma. A 
review of seventy cases, J Bone Joint Surg Am 67(5) (1985) 748-55. 
[7] R. Suneja, R.J. Grimer, M. Belthur, L. Jeys, S.R. Carter, R.M. Tillman, A.M. Davies, 
Chondroblastoma of bone: long-term results and functional outcome after intralesional curettage, J 
Bone Joint Surg Br 87(7) (2005) 974-8. 
[8] S. Viswanathan, N.A. Jambhekar, N.H. Merchant, A. Puri, M. Agarwal, Chondroblastoma of 
bone--not a " benign disease": clinico-pathologic observations on sixty cases, Indian J Pathol 
Microbiol 47(2) (2004) 198-201. 
[9] H. Xu, D. Nugent, H.L. Monforte, O.T. Binitie, Y. Ding, G.D. Letson, D. Cheong, X. Niu, 
Chondroblastoma of bone in the extremities: a multicenter retrospective study, J Bone Joint Surg 
Am 97(11) (2015) 925-31. 
[10] E. Konishi, Y. Nakashima, M. Mano, Y. Tomita, T. Kubo, N. Araki, E. Morii, H. Yoshikawa, 
H. Haga, J. Toguchida, T. Ueda, M. Osawa, M. Hoshi, T. Inoue, M. Aono, A. Yanagisawa, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Chondroblastoma of extra-craniofacial bones: Clinicopathological analyses of 103 cases, Pathology 
international 67(10) (2017) 495-502. 
[11] J.R. Crim, R.H. Gold, J.M. Mirra, J. Eckardt, Case report 748: Chondroblastoma of the femur 
with an aneurysmal bone cyst, Skeletal radiology 21(6) (1992) 403-5. 
[12] D.C. Dahlin, J.C. Ivins, Benign chondroblastoma. A study of 125 cases, Cancer 30(2) (1972) 
401-13. 
[13] M.V. de Silva, R. Reid, Chondroblastoma: varied histologic appearance, potential diagnostic 
pitfalls, and clinicopathologic features associated with local recurrence, Ann Diagn Pathol 7(4) 
(2003) 205-13. 
[14] A. Angelini, F. Arguedas, A. Varela, P. Ruggieri, Chondroblastoma of the Foot: 40 Cases 
From a Single Institution, J Foot Ankle Surg 57(6) (2018) 1105-1109. 
[15] M. Christie-Large, N. Evans, A.M. Davies, S.L. James, Radiofrequency ablation of 
chondroblastoma: procedure technique, clinical and MR imaging follow up of four cases, Skeletal 
radiology 37(11) (2008) 1011-7. 
[16] T. Petsas, P. Megas, Z. Papathanassiou, Radiofrequency ablation of two femoral head 
chondroblastomas, European journal of radiology 63(1) (2007) 63-7. 
[17] L.D. Rybak, D.I. Rosenthal, J.C. Wittig, Chondroblastoma: radiofrequency ablation--
alternative to surgical resection in selected cases, Radiology 251(2) (2009) 599-604. 
[18] B. Tins, V. Cassar-Pullicino, I. McCall, P. Cool, D. Williams, D. Mangham, Radiofrequency 
ablation of chondroblastoma using a multi-tined expandable electrode system: initial results, 
European radiology 16(4) (2006) 804-10. 
[19] C.D.M. Fletcher, WHO Classification of Tumours of Soft Tissue and Bone, Fourth Edition ed., 
IARC, Lyon, 2013. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
[20] M. Tamura, M. Oda, I. Matsumoto, S. Sawada-Kitamura, G. Watanabe, Chondroblastoma with 
pulmonary metastasis in a patient presenting with spontaneous bilateral pneumothorax: Report of a 
case, Surg Today 41(10) (2011) 1439-41. 
[21] S.H. Sohn, S.A. Koh, D.G. Kim, S.W. Park, K.H. Lee, M.K. Kim, J.H. Choi, M.S. Hyun, A 
case of spine origin chondroblastoma metastasis to lung, Cancer research and treatment : official 
journal of Korean Cancer Association 41(4) (2009) 241-4. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
1a. Radiograph showing a chondroblastoma located in the epiphysis of the proximal part of the 
femur 
 
1b.  T2-weighted MRI showing the bone lesion in proximal part of the femur. Note the marrow 
oedema of the epiphysis and metaphysis surrounding the chondroblastoma. 
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Figure 2a. Radiograph showing a chondroblastoma located in the proximal part of the tibia. 
 
 
Figure 2b. T2-weighted MRI showing significant aneurysmal bone cyst component in the 
chondroblastoma in proximal tibia.  
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Figure 3. Illustration showing the site distribution of the 177 lesions.  
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Figure 4a. Curettage sample of a chondroblastoma with prominent secondary ABC like features. 
Small tumour fragments consisting of solid sheets of mononuclear cells with irregular nuclear 
outline are noted. Scattered giant cells are seen. 
 
 
 
Figure 4b. Pale eosinophilic chondroid deposits are also noted.  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Figure 5. The incidence of femoral head tumours according to age.  
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Table 1 
 
Characteristics 
Number 
Eligible patients 177 
Location 
Proximal tibia 
Proximal humerus 
Proximal femur 
Distal femur 
Foot 
Talus 
Calcaneus 
Navicular  
Patella 
Pelvis 
Distal fibula 
Proximal ulna 
Proximal fibula 
Scapula 
Distal humerus 
Hand 
 
36 (20.3%) 
34 (19.2%) 
32 (18.1%) 
28 (15.8%) 
26 (14.7%) 
18/26 (69%) 
7/26 (27%) 
1/26 (4%) 
5 (2.8%) 
4 (2.3%) 
3 (1.7%) 
2 (1.1%) 
1 (0.6%) 
1 (0.6%) 
1 (0.6%) 
1 (0.6%) 
Gender 
Male 
Female 
 
124 (70.1%) 
53 (9.9%) 
Special histological features 
Significant secondary ABC component 
Patella 
Foot 
Proximal femur 
Proximal tibia 
Distal femur 
Atypical chondroblastoma 
Giant cell rich 
 
47 (26.6%) 
5 (100%) 
12 (46.2%) 
10 (31.3%) 
8 (22.2%) 
6 (21.4%) 
10 (5.6%) 
4 (2.3%) 
Local recurrence 
Proximal tibia 
Proximal femur 
Proximal humerus 
Distal femur 
24 (13.6%) 
8/36 (22.2%) 
3/32 (9.4%) 
4/34 (11.8%) 
4/28 (9.4%) 
Metastasizing disease 2 (1.1%) 
Mean time to local recurrence in months (range) 17.6 (3-158) 
Mean age in years (range) 18.3 (8-48) 
Mean size of the tumour in mm (range) 36 (10-100) 
Mean duration of symptoms in weeks (range) 49 (0-208) 
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Table 2 
 
 Greater trochanter Femoral head p-value 
Number 18 14  
Mean age in years 19.5 13.9 0.004 
Duration of symptoms in weeks 64 50 0.659 
Size in mm 53 26 0.001 
Local recurrence 0/18 3/14 0.073 
Male gender 13/18 11/14 0.504 
Secondary ABC component 2/18 2/14 0.597 
Giant cell rich component 1/18 1/14 0.691 
 
 
